211 related articles for article (PubMed ID: 20705882)
21. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group.
Top FH; Connor EM; Carlin DA
Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456
[No Abstract] [Full Text] [Related]
22. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
23. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
Fitzgerald DA
Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
[TBL] [Abstract][Full Text] [Related]
24. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
25. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection.
Mori M; Watabe S; Taguchi T; Hasegawa H; Ishige M; Tanuma N; Hirakawa A; Koike R; Kusuda S
BMC Pediatr; 2021 Mar; 21(1):106. PubMed ID: 33653291
[TBL] [Abstract][Full Text] [Related]
26. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
27. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
28. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).
Bollani L; Baraldi E; Chirico G; Dotta A; Lanari M; Del Vecchio A; Manzoni P; Boldrini A; Paolillo P; Di Fabio S; Orfeo L; Stronati M; Romagnoli C;
Ital J Pediatr; 2015 Dec; 41():97. PubMed ID: 26670908
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
Gonzales T; Bergamasco A; Cristarella T; Goyer C; Wojdyla M; Oladapo A; Sawicky J; Yee J; Moride Y
Am J Perinatol; 2024 May; 41(S 01):e1107-e1115. PubMed ID: 36452969
[TBL] [Abstract][Full Text] [Related]
30. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
[TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
32. Palivizumab for preterm infants. Is it worth it?
Embleton ND; Harkensee C; Mckean MC
Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
[TBL] [Abstract][Full Text] [Related]
33. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
35. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
36. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
[TBL] [Abstract][Full Text] [Related]
37. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).
Paes B; Mitchell I; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2703-11. PubMed ID: 22546928
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
